Clinical Metagenomic Next-Generation Sequencing for Pathogen Detection.
Wei Gu, Steve Miller, Charles Y Chiu
https://pubmed.ncbi.nlm.nih.gov/30355154/Actively Recruiting
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2026-09-16
6500
Participants Needed
6
Research Sites
N/A
Total Duration
Vector-borne diseases, caused by bites from infected insects like mosquitoes and ticks, are a major health concern worldwide, causing nearly 1 million deaths annually. These illnesses are increasing, especially in Southeast Asia, with about 10 percent of fevers in Cambodia linked to such infections. Many cases go undiagnosed due to limited diagnostic resources, so researchers aim to better understand these diseases and identify infectious causes of unexplained fevers using advanced genetic sequencing methods. Participants include individuals aged at least 2 months who have a fever of 38 degrees Celsius or higher, or who are diagnosed with certain high-risk pathogens. Close contacts of infected individuals may also join the study. Participants provide information about their health, travel history, and demographics. Blood samples and nasal swabs if respiratory symptoms are present are collected for testing. Optional follow-up samples may be collected within 1 to 2 weeks andor up to 3 months after enrollment. During the study, participants answer health questionnaires and undergo blood and nasal testing to detect pathogens and immune responses. Researchers analyze pathogen genetic sequences and assess reactions to insect saliva proteins. The study includes initial enrollment and optional follow-up visits to track infections and immune changes over time. Total participation duration varies depending on follow-up involvement.
CONDITIONS
Febrile Disease Landscape in Cambodia Via Metagenomic Pathogen Sequencing
C
Christina C Yek, M.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - At enrollment (Day 0 to 2)
Participants provide health information, answer questionnaires, and give blood samples. Those with respiratory symptoms provide nasal swabs. Close contacts may also participate.
1 visit (in-person)
Duration - Up to 3 months after enrollment
Participants may be contacted within 1 to 2 weeks and/or within 3 months to provide additional blood and nasal samples for further testing.
1 to 2 visits (optional)
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Wei Gu, Steve Miller, Charles Y Chiu
https://pubmed.ncbi.nlm.nih.gov/30355154/Sirenda Vong, Virak Khieu, Olivier Glass...
https://pubmed.ncbi.nlm.nih.gov/21152061/Ala Tabor, Manuel Rodriguez Valle
https://pubmed.ncbi.nlm.nih.gov/30279400/National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor